Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery

ConditionAge-related Cataract

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age60+

SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

To compare treatment with preservative-free dexamethasone 0.1% (Monofree Dexamethason) and diclofenac 0.1% (Dicloabak) eye drops versus preserved dexamethasone 0.1% (Maxidex) and diclofenac 0.1% (Voltaren Ophtha) eye drops after cataract surgery in terms of postoperative inflammation, iatrogenic dry eye disease and cystoid macular edema.

Eligibility criteria

Qualifiers

Patients diagnosed with age-related cataract

Age 60 years or above

Disqualifiers

Unwilling to sign informed consent

Pseudoexfoliation syndrome

Functionally monocular patient

Any use of eye drops during at least 3 months before surgery with the exception of artificial tears

Trial design

Treatments tested in this trial

Preservative Free drop treatment
Preserved drop treatment

Treatment groups

100 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Universitaire Ziekenhuizen KU Leuven

Lead sponsor

Laboratoires Thea

Collaborator

Source ClinicalTrials.gov